You are here

Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection

Last updated on May 12, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacterial Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Written informed consent will be obtained prior to enrollment into the study. If any
patient is unable to give consent, it may be obtained from next of-kin or a legal
representative if in accordance with local laws and regulations

- Hospitalized, ≥18 years of age

- Male or non-pregnant, non-lactating female who is post-menopausal, surgically
sterilized or is using birth control pills, contraceptive implant or injection (ex:
NORPLANT®; DEPO-PROVERA®), intra-uterine device, barrier methods with spermicide, or
abstinence. (Effective contraception should have been in place for at least two months
prior to study entry and must continue for at least 30 days after treatment
discontinuation)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with underlying immunodeficiency disease or patients requiring chronic
treatment with known immunosuppressant medications including >5mg/day prednisone

- Active or treated leukemia, or systemic malignancy that required treatment with
chemotherapy, immunotherapy, radiation therapy, or antineoplastic therapy within the
past year or which is anticipated to begin prior to the Test-of-Cure visit; or any
known or suspected malignancy to the abdomen

- Concurrent hemodialysis, peritoneal dialysis or patients with indwelling peritoneal
catheters or shunts, plasmapheresis or hemoperfusion

NCT00044928
Pfizer
Completed
Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Respiratory Tract Infections
NCT03529773
All Genders
18+
Years
Multiple Sites
Pneumococcal Infections
NCT03512288
All Genders
0+
Years
Multiple Sites
Pneumococcal Pneumonia, Community Acquired Infections, Gram-positive Bacterial Infections
NCT00035269
All Genders
13+
Years
Multiple Sites
Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection
Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection
A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal infection.
Not Provided
Interventional
Phase 4
Primary Purpose: Treatment
Bacterial Infections
Drug: Piperacillin/Tazobactam
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
262
February 2004
February 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Written informed consent will be obtained prior to enrollment into the study. If any patient is unable to give consent, it may be obtained from next of-kin or a legal representative if in accordance with local laws and regulations
  • Hospitalized, ?18 years of age
  • Male or non-pregnant, non-lactating female who is post-menopausal, surgically sterilized or is using birth control pills, contraceptive implant or injection (ex: NORPLANT®; DEPO-PROVERA®), intra-uterine device, barrier methods with spermicide, or abstinence. (Effective contraception should have been in place for at least two months prior to study entry and must continue for at least 30 days after treatment discontinuation)

Exclusion Criteria

  • Patients with underlying immunodeficiency disease or patients requiring chronic treatment with known immunosuppressant medications including >5mg/day prednisone
  • Active or treated leukemia, or systemic malignancy that required treatment with chemotherapy, immunotherapy, radiation therapy, or antineoplastic therapy within the past year or which is anticipated to begin prior to the Test-of-Cure visit; or any known or suspected malignancy to the abdomen
  • Concurrent hemodialysis, peritoneal dialysis or patients with indwelling peritoneal catheters or shunts, plasmapheresis or hemoperfusion
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00044928
0910X-101074
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor, MD Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
February 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now